<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03994029</url>
  </required_header>
  <id_info>
    <org_study_id>2019-2278</org_study_id>
    <nct_id>NCT03994029</nct_id>
  </id_info>
  <brief_title>Effect of Polyphenol Supplementation on Hepatic Steatosis and Vascular Compliance</brief_title>
  <official_title>Effect of Polyphenol Supplementation on Hepatic Steatosis, Non-invasive Vascular Elastography and Intima Media Thickness in Obese Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Justine's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Justine's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to study the effect of polyphenol supplementation on hepatic steatosis&#xD;
      as measured by hepatic ultrasound, hepatic elastography and magnetic resonance hepatic&#xD;
      spectroscopy in obese adolescents known for hepatic steatosis as diagnosed by liver biopsy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obesity leads to hepatic steatosis. Early changes in vascular compliance due to obesity have&#xD;
      been shown to be reversible. Many studies have shown a positive effect of polyphenols&#xD;
      (natural product in apples and grapes) on the liver fat burden. Three visits will be&#xD;
      planified.&#xD;
&#xD;
      Visit 1: Demographic data and liver and vascular imaging. Blood and stool tests.&#xD;
&#xD;
      Randomization to polyphenol versus placebo. Visit 2 at 60 days. Demographic data and liver&#xD;
      and vascular imaging. Blood tests. Stop the intervention.&#xD;
&#xD;
      Visit 3 at 120 days. Demographic data and liver and vascular imaging. Blood and stool tests.&#xD;
&#xD;
      This study will determine the feasibility of a randomized controlled trial evaluating the&#xD;
      effect of polyphenols on hepatic steatosis and the vascular subclinical radiologic changes&#xD;
      related to obesity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 4, 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in hepatic steatosis MR</measure>
    <time_frame>At recruitment, after 60 days, and after 120 days</time_frame>
    <description>MR spectroscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in hepatic steatosis US Shear wave elastography</measure>
    <time_frame>At recruitment, after 60 days, and after 120 days</time_frame>
    <description>US elastography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in hepatic steatosis B-mode US</measure>
    <time_frame>At recruitment, after 60 days, and after 120 days</time_frame>
    <description>Conventional US</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in intima media thickness</measure>
    <time_frame>At recruitment, after 60 days, and after 120 days</time_frame>
    <description>Measurement of carotid artery intima media thickness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in vascular compliance</measure>
    <time_frame>At recruitment, after 60 days, and after 120 days</time_frame>
    <description>Non invasive vascular elastography</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Obesity, Childhood</condition>
  <condition>Hepatic Steatosis</condition>
  <condition>Intimal Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Polyphenol supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>120mg per day of powder polyphenol for 60 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 tab PO QD per day of placebo for 60 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Effect of polyphenols on hepatic steatosis and vascular elastography and intima media thickness</intervention_name>
    <description>Measurement of effect of polyphenol supplementation vs placebo on hepatic steatosis and vascular elastography and intima media thickness</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Polyphenol supplementation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adolescents 12-&lt; 18&#xD;
&#xD;
          -  Residing in the Montreal area&#xD;
&#xD;
          -  BMI &gt; 20-24Kg/mÂ² (&gt; 85th percentile for age and sex)&#xD;
&#xD;
          -  Hepatic MRI spectroscopy showing ratio &gt; 5.5% lipid/water&#xD;
&#xD;
          -  Not being pregnant (if sexually active, using an effective contraceptive method)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  chronic disease, including diabetes, hypercholesterolemia, hypertension, hepatitis&#xD;
             (viral and autoimmune), Wilson's disease and Alpha 1 antitrypsin.&#xD;
&#xD;
          -  Taking medications or supplements&#xD;
&#xD;
          -  Having a significant weight loss in the last 6 months prior to recruitment&#xD;
&#xD;
          -  Alcohol consumption &gt; 2 drinks per day or consume more than 1 day per week&#xD;
&#xD;
          -  Known peanut allergies&#xD;
&#xD;
          -  Contraindications for MRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ramy El Jalbout, MD MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Justine's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Principal investigator</last_name>
    <phone>5143454931</phone>
    <email>ramy.el-jalbout.hsj@ssss.gouv.qc.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Sainte-Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramy El Jalbout, MD</last_name>
      <email>ramy.jalbout@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Anik Cloutier, MSc</last_name>
      <email>anik.cloutier2.hsj@ssss.gouv.qc.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 12, 2019</study_first_submitted>
  <study_first_submitted_qc>June 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2019</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Justine's Hospital</investigator_affiliation>
    <investigator_full_name>Ramy El Jalbout</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Pediatric Obesity</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

